Solutions - Page 21

Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for $330 million, the South Korean biosimilar specialist said it will spend another 700 billion won ($478 million) to upgrade

In a bid to deepen its manufacturing foothold in the U.S., Regeneron Pharmaceuticals in April pledged production and infrastructure investments surpassing $7 billion across North Carolina and its native Empire State. Now,

The company will spend approximately $1.5 billion in capital investments to grow its U.S. plasma-based manufacturing capabilities over the next five years.

South Korea’s Boryung Corporation continues to boost its production footprint by kicking off a project that will double the capacity of its penicillin manufacturing facility in its home country.

Since the start of the month, several drug recalls have entered the FDA’s periphery, affecting products ranging from hospital drugs and potassium deficiency injections to antibiotics and a generic medicine for attention-deficit/hyperactivity

Like with the August cuts, the latest round of layoffs will mostly affect the team based in Harmans, Maryland.

This week on “The Top Line,” we break down what’s known about FDA’s PreCheck, and the parts of the plan that could have the biggest impact on manufacturers.

Cencora plans to spend $1 billion over the next five years to expand its operations in the U.S., including opening a second national distribution center in Ohio.

Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that patients’ appetite